This study will test whether it is safe and effective to use stereotactic body radiation therapy (SBRT)-a short, targeted form of radiation-together with a microultrasound (microUS)-guided radiation boost to the cancerous spots inside the prostate. Researchers will compare treatment plans that use microUS to plans created using the current standard method, which relies on MRI images, to determine whether microUS can successfully guide targeted radiation.
Histologically confirmed carcinoma of the prostate (biopsy results with 12 months of enrollment)
Intermediate risk as defined by NCCN criteria
Conventional imaging (bone scan and abdominal pelvic computed tomography) is mandatory for NCCN unfavourable intermediate risk prostate cancer patients with PSA > 10. Negative nodal, skeletal or visceral metastases within 16 weeks of enrollment (for patients requiring staging). Alternatively, patients with no signs of extra-prostatic disease on PSMA-PET scans are also candidates for this trial
ECOG performance status 0-1
Estimated prostate volume > 60cc (volume based on transrectal ultrasound)
Prior TURP
Prior prostate cancer treatment, including 5-alpha reductase inhibitor treatment
Low, high or very high-risk disease as per NCCN guidelines